Penumbra (BSP:P2NB34) Cyclically Adjusted PS Ratio: (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:P2NB34 Penumbra Inc BSP:P2NB34
21 GF Score
Price R$55.13
GF Value R$57.24
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Penumbra Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Penumbra  (BSP:P2NB34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Penumbra Cyclically Adjusted PS Ratio Related Terms


Penumbra Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Penumbra's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra Cyclically Adjusted PS Ratio Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 12.32 14.10

Penumbra Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.23 11.86 14.10 14.17 13.08

BSP:P2NB34 vs GMED, GKOS, BIO: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Penumbra's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Penumbra's Cyclically Adjusted PS Ratio falls into.


BSP:P2NB34
21GF Score
Penumbra Inc BSP:P2NB34
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Penumbra's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Penumbra's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=50.506/333.9520*333.9520
=50.506

Current CPI (Jun. 2026) = 333.9520.

Penumbra Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.475 241.428 8.956
201612 7.252 241.432 10.031
201703 7.243 243.801 9.921
201706 7.995 244.955 10.900
201709 7.370 246.819 9.972
201712 7.364 246.524 9.976
201803 9.376 249.554 12.547
201806 11.448 251.989 15.172
201809 13.413 252.439 17.744
201812 11.122 251.233 14.784
201903 13.622 254.202 17.896
201906 14.288 256.143 18.628
201909 15.844 256.759 20.607
201912 16.410 256.974 21.326
202003 18.453 258.115 23.875
202006 15.405 257.797 19.956
202009 22.531 260.280 28.908
202012 23.614 260.474 30.275
202103 25.403 264.877 32.028
202106 24.654 271.696 30.303
202109 26.684 274.310 32.486
202112 29.773 278.802 35.662
202203 26.213 287.504 30.448
202206 27.845 296.311 31.382
202209 29.549 296.808 33.247
202212 30.510 296.797 34.329
202303 32.178 301.836 35.602
202306 32.378 305.109 35.439
202309 34.118 307.789 37.018
202312 35.479 306.746 38.626
202403 35.231 312.332 37.670
202406 41.570 314.175 44.187
202409 42.552 315.301 45.069
202412 47.006 315.605 49.739
202503 47.658 319.799 49.767
202506 47.968 322.561 49.662
202509 48.399 324.800 49.763
202512 53.344 324.054 54.973
202603 49.561 330.213 50.122
202606 50.506 333.952 50.506

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Penumbra (BSP:P2NB34) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of R$55.13 is trading 3.7% below its estimated GF Value™ of R$57.24. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for BSP:P2NB34:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: R$57.24 vs. price of R$55.13 (3.7% below fair value)
  • GF Score™: 21/100 with 1 warning sign

No single metric tells the full story. See the BSP:P2NB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Penumbra Business Description

Other Exchanges PEN:USA
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
21GF Score

Get the complete analysis for BSP:P2NB34

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$55.13
Price
R$57.24
GF Value